Gene therapy shot aims to tame wet AMD in both eyes

NCT ID NCT07630649

Recruiting now Disease control Sponsor: Adverum Biotechnologies, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Aug 06, 2026 · Updated 2 times

Summary

This study tests a gene therapy called Ixo-vec in the second eye of people with wet age-related macular degeneration (AMD) in both eyes. Fifteen adults aged 50 and older will receive a single injection in the second eye and be followed for about 5 years. The goal is to see if the treatment is safe and can reduce the need for regular eye injections to control the disease.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Ixoberogene soroparvovec (Ixo-vec) gene therapy
What this could lead to: If successful, this could show that a single injection of gene therapy in each eye can reduce the need for frequent anti-VEGF injections to control wet AMD.
What could go wrong: This is a small, early-phase study with only 15 participants. Gene therapy carries risks like inflammation or vision changes, and it may not work as well in the second eye or last long-term.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BILATERAL NEOVASCULAR (WET) AGE-RELATED MACULAR DEGENERATION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

blindness (disorder) eye disorder macular degeneration wet macular degeneration

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) WET AMD

Contacts and locations

Locations

Adverum site 107
RECRUITING

The Woodlands, Texas, 77384, United States
Adverum site 109
RECRUITING

Bakersfield, California, 93309, United States
Adverum site 122
RECRUITING

West Columbia, South Carolina, 29169, United States
Adverum site 124
RECRUITING

Deerfield Beach, Florida, 33064, United States
Adverum site 126
RECRUITING

Phoenix, Arizona, 85053, United States
Adverum site 149
RECRUITING

‘Aiea, Hawaii, 96701, United States
Adverum site 168
RECRUITING

Jacksonville, Florida, 32216, United States
Adverum site 169
RECRUITING

Fullerton, California, 92835, United States
Adverum site 171
RECRUITING

Teaneck, New Jersey, 07666, United States
Adverum site 176
RECRUITING

Fort Lauderdale, Florida, 33308, United States
Adverum site 179
RECRUITING

Lemont, Illinois, 60439, United States
Adverum site 231
RECRUITING

The Woodlands, Texas, 77384, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.